Three dimensional conformal photon radiotherapy at a moderate dose level of 66 Gy for prostate carcinoma: Early results

Strahlentherapie und Onkologie

Volumn 175, Issue SUPPL. 2, 1999, Pages 84-86

  Wachter, Stefan ^a   Gerstner, Natascha ^b   Goldner, Gregor ^b   Dieckmann, Karin ^b   Colotto, Adriana ^b   Pötter, Richard ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Conformal photon radiotherapy; Early response; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; BEAM THERAPY; CANCER CONTROL; CONFERENCE PAPER; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PROSTATE CARCINOMA; RADIATION DOSE; UNIVERSITY HOSPITAL;

EID: 0032718401     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03038898     Document Type: Conference Paper

References (11)

1. Fukunaga-Johnson N, Sandler HM, McLaughlin PW, et al. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;38:311-17.
2. Hanks GE, Lee WR, Hanlon AL, et al. Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/ml. Int J Radial Oncol Biol Phys 1996;35:861-8.
3. Hanks GE, Schultheiss TE, Hanlon AL, et al. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys 1997;37:543-50.
4. Hanks GE, Schultheiss TE, Hunt MA, et al. Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1995;31:25-9.
5. Kavadi VS, Zagars GK, Pollack A. Serum prostatic-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys 1994;30:279-87.
6. Schultheiss TE, Lee WR, Hunt MA, et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997:37: 3-11.
7. Soffen EM, Hanks GE, Hunt MA, et al. Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity. Int J Radial Oncol Biol Phys 1992;24:485-8.
8. Tait DM, Nahum AE, Meyer LC, et al. Acute toxicity in pelvic radiotherapy: a randomised trial of conformal versus conventional treatment. Radiother Oncol 1997;42:121-36.
9. Wachter S, Gerstner N, Dieckmann K, et al. Factors predicting for late rectal morbidity after 3-d-planned radiotherapy of localized prostate cancer. Radiother Oncol 1996;40(suppl. 1):184.
10. Wachter S, Gerstner N, Dieckmann K, et al. Dreidimensional geplante kleinvolumige Konformationsbestrahlung des lokalen Prostatakarzinoms. Strahlenther Onkol 1997;5:253-60.
11. Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol 1994;152:1786-91.